{
}
Goldman Sachs has raised its price target for AstraZeneca shares to £151.30, maintaining a Conviction Buy rating, citing an 18% revenue growth and potential in the oral PCSK9 inhibitor market with AZD0780. The anticipated Phase 2 PURSUIT trial data, due on March 31, 2025, is expected to significantly impact the competitive landscape. AstraZeneca is also investing $2.5 billion in a new R&D center in Beijing, enhancing its presence in China and focusing on early-stage research and clinical development.
Roche has entered a $1 billion deal with Innovent Biologics for the DLL3-targeted ADC IBI3009, following promising data from Zai Lab's DLL3 ADC in small cell lung cancer. AstraZeneca faces scrutiny in China, potentially impacting operations, while Viatris received an FDA warning letter for its Indian plant, affecting 11 products. In other developments, Ideaya Biosciences is paying $75 million for rights to SHR-4849, and Hutchmed is divesting its interest in a traditional medicine unit to focus on ADCs.
AstraZeneca Plc is shifting its focus to the US for growth as challenges in its previously booming China market intensify, impacted by an ongoing investigation that has affected its stock price. CEO Pascal Soriot outlined the company's ambitions in the US, highlighting significant investments in research and development while announcing an increase in its annual earnings forecast.
Pascal Soriot
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Goldman Sachs raises AstraZeneca target amid promising drug development and expansion
08:50 28.03.2025
biopharma deals and challenges emerge in asia with focus on adc developments
VBI Vaccines Inc.
Shanghai Pharmaceuticals Holding Co., Ltd
Hoffmann-La Roche AG
Lonza Group AG
AstraZeneca PLC
I-Mab
SK bioscience Co.,Ltd.
Zai Lab Ltd
IDEAYA Biosciences, Inc.
Brii Biosciences Ltd.
HUTCHMED
Sanofi
BeiGene, Ltd.
Innovent Biologics, Inc.
Viatris Inc.
Cytokinetics, Incorporated
CHN
IND
Yong Ying-I
Pascal Soriot
Show more
14:37 03.01.2025
AstraZeneca shifts focus to US growth amid challenges in China
14:53 12.11.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Global Financial Events
Banking Regulations
Global Trade Developments
Domestic Politics
Retail and Consumer Goods
Central Bank Actions
CEO Changes
Government Policies
Market Analysis and Predictions
Workplace Trends
Startups & Entrepreneurship
Elections & Campaigns
Government Economic Policies
Inflation and Monetary Impact
Supply Chain Management
Countries:
Companies:
Tesla, Inc.
Barclays PLC
JPMorgan Chase & Co.
Deutsche Bank Money Market PP
Apple Inc.
UniCredit S.p.A.
Banco BPM S.p.A.
Credit Suisse Strategic Income I
The Goldman Sachs Group, Inc.
SpaceXCoin USD
Lloyds Banking Group plc
BNP Paribas SA
UBS Group AG
Banco Santander, S.A.
CREDIT AGRICOLE
Amazon.com, Inc.
Credit Agricole
Berkshire Hathaway Inc.
Reinsurance Group of America, Incorporated
Google Inc.
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Canadian Dollar
Australian Dollar
Offshore Chinese Yuan
Hong Kong Dollar
Singapore Dollar
Mexican Peso
Vietnamese Đồng
Indonesian Rupiah
Thai Baht
Norwegian Krone
Swedish Krona
Filipino Peso
People: